Patients with clinically suspected MEN1 exhibit a significantly higher risk for various metabolic syndromes, including diabetes, hypertension, hyperlipidemia, cardiovascular diseases, and malignancies, with a HR for mortality 3.7-fold higher than that of controls. This evidence concerns the gene MEN1 and metabolic syndrome.